Next Generation Cancer Diagnostics Global Market Report 2025

Description

Next generation cancer diagnostics refers to advanced diagnostic technologies that enable precise detection, characterization, and monitoring of cancer at the molecular and genetic levels. These diagnostics use cutting-edge tools such as genomics, proteomics, and liquid biopsy to support early detection, personalized treatment planning, and improved patient outcomes.

The main technologies used in next generation cancer diagnostics include next-generation sequencing (NGS), q-polymerase chain reaction and multiplexing, lab-on-a-chip (LOAC) and reverse transcriptase-polymerase chain reaction (RT-PCR), circulating tumor deoxyribonucleic acid (ctDNA) assays, protein microarrays, deoxyribonucleic acid microarrays, and others. Next-generation sequencing (NGS) is a high-throughput DNA sequencing method that enables rapid, simultaneous sequencing of millions of DNA fragments, allowing comprehensive analysis of genomes, transcriptomes, and genetic variations. These technologies target various cancer types, including lung cancer, breast cancer, colorectal cancer, and cervical cancer. Their functions include therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. They are applied in biomarker development, circulating tumor cell (CTC) analysis, proteomic analysis, epigenetic analysis, and genetic analysis, and serve end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, pharmaceutical and biotechnology companies, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The next generation cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides next generation cancer diagnostics market statistics, including next generation cancer diagnostics industry global market size, regional shares, competitors with a next generation cancer diagnostics market share, detailed next generation cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next generation cancer diagnostics industry. This next generation cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next generation cancer diagnostics market size has grown rapidly in recent years. It will grow from $12.71 billion in 2024 to $14.40 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period resulted from the increasing prevalence of cancer worldwide, growing adoption of molecular diagnostics, rising demand for early cancer detection, expansion of healthcare infrastructure, and greater use of biomarker-based screening.

The next generation cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $23.45 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period will be driven by a rising focus on precision oncology, increasing demand for minimally invasive diagnostic techniques, growing adoption of artificial intelligence and digital tools in cancer detection, expansion of genomic testing services, and increasing government funding for cancer research. Major trends in the forecast period include the development of non-invasive diagnostic assays, integration of cloud-based data analytics, innovations in nanotechnology-based biosensors, incorporation of real-world evidence and clinical data, and the integration of robotics and automation.

The rising demand for personalized medicines is expected to drive the expansion of the next-generation cancer diagnostics market in the coming years. Personalized medicines are treatments tailored to an individual's genetic makeup, lifestyle, and environment to ensure the most effective therapy for each patient. This demand is fueled by the growing prevalence of chronic and rare diseases, which require targeted, patient-specific treatments for better clinical outcomes. Next-generation cancer diagnostics support personalized medicine by providing precise molecular insights that inform customized treatment strategies based on a patient's unique genetic and tumor profile. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Consequently, the rising demand for personalized medicines is driving the growth of the next-generation cancer diagnostics market.

Key players in the next-generation cancer diagnostics market are developing innovative solutions such as artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized therapy, and clinical decision-making. These AI-powered multi-modal platforms integrate and analyze diverse biological data-including genomic, proteomic, imaging, and clinical information-to deliver more accurate and individualized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform designed for precision oncology. The platform combines circulating tumor DNA, single-cell circulating tumor cells, RNA data, and detailed protein profiles of 150 proteins at the single-cell level. Using a 1,080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to improve clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell's proprietary iDiscover application from a CLIA-certified laboratory.

In June 2023, Quest Diagnostics Inc., a US-based healthcare diagnostics company, acquired Haystack Oncology for an undisclosed amount. This acquisition aimed to strengthen Quest Diagnostics' capabilities in the rapidly growing minimal residual disease (MRD) liquid biopsy market. Haystack Oncology Inc., a US-based firm, provides next-generation cancer diagnostics through its tumor-informed MRD test, Haystack MRD.

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

North America was the largest region in the next generation cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next generation cancer diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation cancer diagnostics market consists of revenues earned by entities by providing services such as genomic and molecular profiling, liquid biopsy testing, next-generation sequencing (NGS) services, companion diagnostics development, and bioinformatics and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation cancer diagnostics market also includes sales of gene panels, single-cell analysis systems, nanotechnology-based biosensors, molecular imaging agents, and exosome isolation kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: Next-Generation Sequencing (NGS); QPolymerase Chain Reaction And Multiplexing; Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR); Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays; Protein Microarrays; Deoxyribonucleic Acid Microarrays; Other Multi-Omics Platforms
2) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Cervical Cancer
3) By Function: Therapeutic Monitoring; Companion Diagnostics; Prognostics; Cancer Screening; Risk Analysis
4) By Application: Biomarker Development; Circulating Tumor Cell (CTC) Analysis; Proteomic Analysis; Epigenetic Analysis; Genetic Analysis
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Pharmaceutical And Biotechnology Companies; Home Care Settings
Subsegments:
1) By Next-Generation Sequencing: Whole Genome Sequencing; Targeted Gene Sequencing; Exome Sequencing; Transcriptome Sequencing
2) By Quantitative Polymerase Chain Reaction And Multiplexing: Quantitative Polymerase Chain Reaction; Digital Polymerase Chain Reaction; Multiplex Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction
3) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays; Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips; Point-of-Care Lab-On-A-Chip Devices; High-Throughput Lab-On-A-Chip Systems
4) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays; Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels; Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays; Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
5) By Protein Microarrays: Analytical Protein Microarrays; Functional Protein Microarrays; Reverse Phase Protein Microarrays; Antibody-Based Protein Microarrays
6) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays; Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays; Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays; Methylation Deoxyribonucleic Acid Microarrays
7) By Other Multi-Omics Platforms: Metabolomics Platforms; Epigenomics Platforms; Transcriptomics Platforms; Integrated Multi-Omics Systems
Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG; Danaher Corporation; Koninklijke Philips N.V.; General Electric Company; Becton, Dickinson and Company; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Exact Sciences Corporation; QIAGEN N.V.; Almac Group Ltd.; Natera Inc.; Myriad Genetics Inc.; NeoGenomics Inc.; Guardant Health Inc.; Freenome Holdings Inc.; Personalis Inc.; Burning Rock Biotech Limited.; SOPHiA GENETICS S.A.; Singlera Genomics Co. Ltd.
Countries:

Product Code: r40068

1. Executive Summary

2. Next Generation Cancer Diagnostics Market Characteristics

3. Next Generation Cancer Diagnostics Market Trends And Strategies

4. Next Generation Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Next Generation Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

5.1. Global Next Generation Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Next Generation Cancer Diagnostics Market Growth Rate Analysis
5.4. Global Next Generation Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Next Generation Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Next Generation Cancer Diagnostics Total Addressable Market (TAM)

6. Next Generation Cancer Diagnostics Market Segmentation

6.1. Global Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Next-Generation Sequencing (NGS)
QPolymerase Chain Reaction And Multiplexing
Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays
Protein Microarrays
Deoxyribonucleic Acid Microarrays
Other Multi-Omics Platforms
6.2. Global Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
6.3. Global Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
6.4. Global Next Generation Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biomarker Development
Circulating Tumor Cell (CTC) Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
6.5. Global Next Generation Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic Laboratories
Research And Academic Institutions
Pharmaceutical And Biotechnology Companies
Home Care Settings
6.6. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Whole Genome Sequencing
Targeted Gene Sequencing
Exome Sequencing
Transcriptome Sequencing
6.7. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Quantitative Polymerase Chain Reaction And Multiplexing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Quantitative Polymerase Chain Reaction
Digital Polymerase Chain Reaction
Multiplex Polymerase Chain Reaction
Reverse Transcription Polymerase Chain Reaction
6.8. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Microfluidic Chip Assays
Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips
Point-of-Care Lab-On-A-Chip Devices
High-Throughput Lab-On-A-Chip Systems
6.9. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Circulating Tumor Deoxyribonucleic Acid Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays
Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels
Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays
Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
6.10. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Protein Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Analytical Protein Microarrays
Functional Protein Microarrays
Reverse Phase Protein Microarrays
Antibody-Based Protein Microarrays
6.11. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Deoxyribonucleic Acid Microarrays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Expression Deoxyribonucleic Acid Microarrays
Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays
Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays
Methylation Deoxyribonucleic Acid Microarrays
6.12. Global Next Generation Cancer Diagnostics Market, Sub-Segmentation Of Other Multi-Omics Platforms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metabolomics Platforms
Epigenomics Platforms
Transcriptomics Platforms
Integrated Multi-Omics Systems

7. Next Generation Cancer Diagnostics Market Regional And Country Analysis

7.1. Global Next Generation Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Next Generation Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Cancer Diagnostics Market

8.1. Asia-Pacific Next Generation Cancer Diagnostics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Cancer Diagnostics Market

9.1. China Next Generation Cancer Diagnostics Market Overview
9.2. China Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Cancer Diagnostics Market

10.1. India Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Cancer Diagnostics Market

11.1. Japan Next Generation Cancer Diagnostics Market Overview
11.2. Japan Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Cancer Diagnostics Market

12.1. Australia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Cancer Diagnostics Market

13.1. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Cancer Diagnostics Market

14.1. South Korea Next Generation Cancer Diagnostics Market Overview
14.2. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Cancer Diagnostics Market

15.1. Western Europe Next Generation Cancer Diagnostics Market Overview
15.2. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Cancer Diagnostics Market

16.1. UK Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Cancer Diagnostics Market

17.1. Germany Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Cancer Diagnostics Market

18.1. France Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Cancer Diagnostics Market

19.1. Italy Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Cancer Diagnostics Market

20.1. Spain Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Cancer Diagnostics Market

21.1. Eastern Europe Next Generation Cancer Diagnostics Market Overview
21.2. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Cancer Diagnostics Market

22.1. Russia Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Cancer Diagnostics Market

23.1. North America Next Generation Cancer Diagnostics Market Overview
23.2. North America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Cancer Diagnostics Market

24.1. USA Next Generation Cancer Diagnostics Market Overview
24.2. USA Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Cancer Diagnostics Market

25.1. Canada Next Generation Cancer Diagnostics Market Overview
25.2. Canada Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Cancer Diagnostics Market

26.1. South America Next Generation Cancer Diagnostics Market Overview
26.2. South America Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Cancer Diagnostics Market

27.1. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Cancer Diagnostics Market

28.1. Middle East Next Generation Cancer Diagnostics Market Overview
28.2. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Cancer Diagnostics Market

29.1. Africa Next Generation Cancer Diagnostics Market Overview
29.2. Africa Next Generation Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Next Generation Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Next Generation Cancer Diagnostics Market, Segmentation By Function, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Cancer Diagnostics Market Competitive Landscape And Company Profiles

30.1. Next Generation Cancer Diagnostics Market Competitive Landscape
30.2. Next Generation Cancer Diagnostics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Cancer Diagnostics Market Other Major And Innovative Companies

31.1. Danaher Corporation
31.2. Koninklijke Philips N.V.
31.3. General Electric Company
31.4. Becton, Dickinson and Company
31.5. Agilent Technologies Inc.
31.6. Illumina Inc.
31.7. Sysmex Corporation
31.8. Bio-Rad Laboratories Inc.
31.9. Exact Sciences Corporation
31.10. QIAGEN N.V.
31.11. Almac Group Ltd.
31.12. Natera Inc.
31.13. Myriad Genetics Inc.
31.14. NeoGenomics Inc.
31.15. Guardant Health Inc.

32. Global Next Generation Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Cancer Diagnostics Market

34. Recent Developments In The Next Generation Cancer Diagnostics Market

35. Next Generation Cancer Diagnostics Market High Potential Countries, Segments and Strategies

35.1 Next Generation Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
35.2 Next Generation Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
35.3 Next Generation Cancer Diagnostics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer